Banco Santander S.A. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Banco Santander S.A. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,478 shares of the biopharmaceutical company’s stock after selling 220 shares during the period. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $5,327,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Proficio Capital Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $127,489,000. KBC Group NV boosted its position in shares of Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $65,180,000. Finally, Icon Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Bank of America reissued an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Robert W. Baird decreased their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Up 1.3 %

REGN stock opened at $707.51 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average is $696.12 and its 200-day moving average is $851.05. The firm has a market cap of $77.35 billion, a P/E ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.